Giant cell arteritis. Part III. New trends in its treatment (role of genetically engineered drugs)
Giant cell arteritis (GCA) is a well-known vasculitis sensitive to glucocorticoid (GC) immuno-suppression. However, during long-term treatment there may be many adverse reactions that remain a serious problem so far. Since GCA encompasses a broad spectrum of clinical subtypes, ranging from severe vi...
Saved in:
| Main Author: | Azamat Makhmudovich Satybaldyev |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2013-03-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/462 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Giant cell arteritis. Part II. Treatment
by: Azamat Makhmudovich Satybaldyev
Published: (2012-12-01) -
Giant cell arteritis. Part I. Terminology, classification, clinical manifestations, diagnosis
by: Azamat Makhmudovich Satybaldyev
Published: (2012-09-01) -
Tocilizumab in Extracranial Giant-Cell Arteritis and Takayasu Arteritis: A Multicentric Observational Comparative Study
by: Carmen Lasa-Teja, et al.
Published: (2025-01-01) -
EXPERIENCE WITH TOCILIZUMAB, AN INTERLEUKIN 6 INHIBITOR, USED FOR THE TREATMENT OF GIANT CELL ARTERITIS WITH SEVERE COMORBIDITY
by: T. V. Beketova, et al.
Published: (2018-05-01) -
Pharmacotherapy of giant cell arteritis and polymyalgia rheumatica: Prospects for the use of monoclonal antibodies to interleukin 6
by: Evgeny L. Nasonov, et al.
Published: (2024-09-01)